多西他赛联合洛铂治疗老年晚期卵巢癌合并腹水的近期疗效观察  

Efficacy Observation of Docetaxel and Lobaplatin Therapy in Recurrent Elderly Advanced Ovarian Carcinoma

作　　者：辛庆锋[1] 

机构地区：[1]漯河医学高等专科学校第三附属医院肿瘤内科,河南漯河462000

出　　处：《中国伤残医学》2015年第17期14-15,共2页Chinese Journal of Trauma and Disability Medicine

摘　　要：目的：观察多西他赛联合洛铂化疗方案治疗老年晚期卵巢癌的临床疗效及其安全性。方法：老年晚期卵巢癌合并腹水患者32例，以多西他赛联合洛铂方案（TL方案）进行化疗：第1天多西他赛75mg／m2静脉滴注、洛铂30mg／m2加入葡萄糖溶液溶解后腹腔内注入化疗，21天为1周期，治疗2个周期后进行评价。结果：总有效率46．9％，其中Ⅲ期、Ⅳ期有效率分别为52．4％、36．4％，差异具有统计学意义（P=0．048〈0．05）；浆液性和黏液性卵巢癌有效率分别为47．4％和46．2％，差异无统计学意义（P=0．121〉0．05）。毒副反应较轻，以Ⅰ～Ⅱ度骨髓抑制为主。结论：TL方案治疗老年晚期卵巢癌疗效好，经对症处理，毒副反应患者可耐受，且有较好的依从性，可作为一线方案使用。Objective： To evaluate the effects and safety of docetaxel and lobaplatin on treating elderly advanced ovarian carcinoma. Methods： A total of 32 patients with recurrent elderly advanced ovarian carcinoma were enrolled, lobaplatin at a dose of 30 mg/m2 intra- venous infusion on dl, and docetaxel at a dose of 75 rag/m2 intravenous infusion on dl. Every 21days was 1 cycle. The efficacy was eval- uated after 2 cycles. Results： The overall response rate （RR = CR ＋ PR） was 46.9 %. The overall response rate was 52.4% in the stage HI patients and 36.4% in the stage IV patients, the deference have statistics significance. The overall response rate was 47.4% in the in the serous ovarian cancer patients and 46.2% in the mucinous ovarian cancer patients, there were no statistical significance. The major ad- verse effects were I - II bone marrow depression. Conclusion ： Combined chemotherapy of lobaplatin and docetaxel has a good anti - tumor activity and manageable toxicity on elderly advanced ovarian carcinoma patients.

关 键 词：多西他赛 洛铂 老年 晚期卵巢癌 

分 类 号：R737.31[医药卫生—肿瘤]